Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma

To join this study, your doctor will check if you meet certain criteria. You would generally need to have a good level of physical activity, meaning you can mostly go about your day without much difficulty. You'll also need to have clear signs of follicular lymphoma that can be measured on scans, and it must be a specific type of follicular lymphoma confirmed by earlier tests.

Crucially, your lymphoma must have come back (relapsed) or not responded well (refractory) to at least one previous treatment that included a medicine called an anti-CD20 antibody combined with chemotherapy. This means if you've only had anti-CD20 medicine by itself or radiation, this study wouldn't be suitable for you.

There are also some reasons why you might not be able to join. For example, if you've previously not responded to lenalidomide, or if you've taken lenalidomide within the last 12 months, you wouldn't be eligible. Your kidney function also needs to be at a certain level.

If you join this study, you will be placed into one of three treatment groups by the study doctors, though one of these groups is already full. You will either receive the standard R2 treatment (rituximab given by a drip and lenalidomide by mouth) or the R2 treatment combined with epcoritamab, which is given as an injection under the skin. The rituximab will be given for up to 5 cycles, and lenalidomide and epcoritamab (if you receive it) will be given for up to 12 cycles. Each cycle lasts 28 days.

Taking part in this study will likely mean more hospital or clinic visits than your usual care would require. During these visits, doctors will perform medical checks, take blood samples, ask about any side effects you might be experiencing, and have you fill out questionnaires. These regular checks are important to see how you are responding to the treatment and to monitor your health. The total duration of your participation will depend on your treatment plan and how you respond.